• #LGM Pharma is a Cetrorelix CAS# 120287-85-6 API supplier distributor based in the USA. Inquire about DMF, cGMP, price, availability, delivery, purity, and more.
  • #Questions? Call our customer API support number 1-(800)-881-8210.
  • #LGM Pharma offers this active ingredient but not the finished dosage forms.

Product Details:

  • CAS No: 120287-85-6
  • AHFC code: 32:00.0
  • Synonyms: Cetrorelix, Cetrorelixum, Cetrorelixum [INN-Latin], Cetrotide, HSDB 7696, SB 75, SB-75, UNII-OON1HFZ4BA
  • ATC Code: H01CC02
  • Chemical Formula: C70-H92-Cl-N17-O14
  • Molecular Weight: 1431.038
  • Assay/Purity: Typically NLT 98%
  • DrugBank: DB00050 (APRD00686, BIOD00115, BTD00115)
  • SMILES: CC(C)C[C,H](NC(=O)[C,,H](CCCNC(N)=O)NC(=O)[C,H](CC1=CC=C(O)C=C1)NC(=O)[C,H](CO)NC(=O)[C,,H](CC1=CN=CC=C1)NC(=O)[C,,H](CC1=CC=C(Cl)C=C1)NC(=O)[C,,H](CC1=CC2=CC=CC=C2C=C1)NC(C)=O)C(=O)N[C,,H](CCCNC(N)=N)C(=O)N1CCC[C,H]1C(=O)N[C,H](C)C(N)=O
  • InChl: SBNPWPIBESPSIF-MHWMIDJBSA-N
  • PubChem: APRD00686
  • IUPAC:

Additional Details

Indication:
For the inhibition of premature LH surges in women undergoing controlled ovarian stimulation
Pharmacodynamics:
Cetrorelix is a synthetic decapeptide with gonadotropin-releasing hormone (GnRH) antagonistic activity. GnRH induces the production and release of luteinizing hormone (LH) and follicle stimulating hormone (FSH) from the gonadotrophic cells of the anterior pituitary. Due to a positive estradiol (E2) feedback at midcycle, GnRH liberation is enhanced resulting in an LH-surge. This LH-surge induces the ovulation of the dominant follicle, resumption of oocyte meiosis and subsequently luteinization as indicated by rising progesterone levels. Cetrorelix competes with natural GnRH for binding to membrane receptors on pituitary cells and thus controls the release of LH and FSH in a dose-dependent manner.
Mode of Action:
Cetrorelix binds to the gonadotropin releasing hormone receptor and acts as a potent inhibitor of gonadotropin secretion. It competes with natural GnRH for binding to membrane receptors on pituitary cells and thus controls the release of LH and FSH in a dose-dependent manner.
Metabolism:
In in vitro studies, cetrorelix was stable against phase I- and phase II-metabolism. Cetrorelix was transformed by peptidases, and the (1-4) peptide was the predominant metabolite.
Toxicity:
General Reference:
Products currently covered by valid US Patents are offered for R&D use in accordance with 35 USC 271(e)+A13(1). Any patent infringement and resulting liability is solely at buyer risk.

API’s From Quality Manufacturers:

  • Cost effective materials based on specific requirements
  • Small quantities for initial research and larger development quantities towards product commercialization

 

  • Technical packages, letters of access to filed DMFs
  • Complete assistance in any regulatory filings
  • Top quality GMP certified manufacturers
  • Have necessary regulatory credentials